We are at an inflection point that is driving a renaissance in antibody-drug conjugate (ADC) development. As successes in the clinic have led to more U.S. Food & Drug Administration (FDA) approvals, ...

The first-in-class antibody-drug conjugate (ADC) pivekimab sunirine (PVEK) demonstrated promising efficacy and high response rates for patients with blastic plasmacytoid dendritic cell neoplasm ...

Third, Enhertu’s cysteine-based conjugation process is able to achieve a high drug-to-antibody ratio of around 7 to 8. This is much higher than the DAR’s of older generations of ADCs, which ...

In classical bacterial conjugation, one bacterium transfers genetic material to another through direct cell-to-cell contact.3 This can either be through a natural process or via artificial means.

An antibody–toxin conjugate targeting CD47 linked to the bacterial toxin listeriolysin O for cancer immunotherapy. Nature Cancer, 2025; DOI: 10.1038/s43018-025-00919-0 ...

GSK’227 (also known as HS-20093) is a novel antibody-drug conjugate (ADC) composed of a fully human anti-B7-H3 monoclonal antibody covalently linked to a topoisomerase inhibitor payload.

Pfizer doubles down on AI partnership with antibody-drug conjugate deal Artificial intelligence start-up PostEra will help the drugmaker design new payloads by Rowan Walrath January 7, 2025 ...

HDP-101, a novel investigational B-cell maturation antigen (BCMA)–targeting antibody-drug conjugate (ADC), demonstrated encouraging efficacy in patients with progressive or refractory multiple ...

TORL-1-23 is a first and potentially best-in-class clinical-stage antibody-drug conjugate (ADC) for the treatment of Claudin 6 positive (CLDN6+) solid tumors. Select centers are enrolling patients in ...

How the Conjugate System Works At the heart of the Westside Barbell method is the conjugate system, which rotates exercises to prevent ‘accommodation’ – a lifting term for stagnation in your ...

Riding high on its Daiichi Sankyo-partnered antibody drug conjugate (ADC) Enhertu—and banking on an approval for its next ADC contender datopotamab deruxtecan this winter—AstraZeneca is ...